It was hard to believe that a baby could be diagnosed with such a serious condition as a brain tumor. Russ was a happy infant who developed normally but by age one he was very thin for his age and had some slight jiggling in one eye. After two days of tests, a CAT scan …
Brendan D. Price, Ph.D., Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA First–Year Funding Summary, going into the second-year Pediatric high-grade gliomas (pHGG) have few treatment options and most children diagnosed only survive for 1-2 years. Identifying new treatments is therefore of the highest priority. Work in the lab is focused …
Jian Teng, Ph.D., Massachusetts General Hospital one-year 2018-2019 final summary I want to take this opportunity to sincerely thank CBTF for your funding to my proposal of using a subset of quinoline methanol anti-malaria agents in killing pediatric brain cancer cells. This funding helps us get one step closer to our goal. With the funding …
Stephen C. Mack, Ph.D., Baylor College of Medicine, Texas Children’s one-year study, final summary We are grateful for support provided by the CBTF and funders that have allowed us to pursue our project on the characterizing “The Role of MOS Proto-Oncogene in H3.3K27M Diffuse Intrinsic Pontine Glioma”. Diffuse intrinsic pontine glioma (DIPG) remains a fatal …
November 10, 2018 Held at Madame Tussaud’s in Washington D.C. This fundraiser was held in celebration of CBTF 25th anniversary of advancing medical research, assisting families with information, and forming a community of support for those touched by childhood brain tumors. The Childhood Brain Tumor Foundation’s 25th Anniversary Gala was held at Madame Tussaud’s in …
Kevin Bielamowicz Poor outcomes for children with high grade glioma (HGG) warrant novel therapeutic strategies, and redirecting immune cells can achieve this aim while minimizing side effects to normal cells. Using mathematical modeling in a group of brain tumor samples, we discovered substantial variation between individual cells within the same tumor as well as between …
Allison Martin, M.D. Medulloblastoma is the most common malignant brain tumor in children. In cases of relapsed or refractory disease there is no known curative therapy. To address this question we have generated fetal mouse brain cells that mimic the most aggressive phenotype of medulloblastoma called “anaplastic” when they are placed into the cerebellum of …
Sign up for the CBTF Newsletter Issued quarterly, our newsletter offers recent articles and events, features, and more!
Sign up for the CBTF Newsletter Issued quarterly, our newsletter offers recent articles and events, features, and more!
